Amylx Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Oxford Lane Capital Corp trades at $9.3 (market cap $909.61M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.9× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | OXLC | |
|---|---|---|
Market Cap | $2.64B | $909.61M |
Sector | Health | Financials |
52-Week High | $24.19 | $18.75 |
52-Week Low | $7.82 | $8.15 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 25.76% |
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →